RÉSUMÉ
We retrospectively assessed whether normalized bone marrow WT1 levels could be used for risk stratification in a consecutive series of 584 acute myeloid leukemia (AML) patients. A cutoff value of 5065 copies at diagnosis identified two prognostic groups (overall survival (OS): 44 ± 3 vs 36 ± 3%, P=0.023; leukemia-free survival (LFS): 47 ± 3 vs 36 ± 4%, P=0.038; and cumulative incidence of relapse (CIR): 37 ± 3 vs 47 ± 4%, P=:0.043). Three groups were identified on the basis of WT1 levels post-induction: Group 0 (WT1 between 0 and 17.5 copies, 134 patients, OS: 59 ± 4%, LFS:59 ± 4% and CIR: 26 ± 4%); Group 1 (WT1 between 17.6 and 170.5 copies, 160 patients, OS: 48 ± 5%, LFS:41 ± 4% and CIR: 45 ± 4%); and Group 2 (WT1 >170.5 copies, 71 patients, OS: 23 ± 6%, LFS: 19 ± 7% and CIR: 68 ± 8%) (P<0.001). Post-intensification samples distinguished three groups: patients with WT1 >100 copies (47 patients, 16%); an intermediate group of patients with WT1 between 10 and 100 copies (148 patients, 52%); and a third group with WT1 <10 copies (92 patients, 32%). Outcomes differed significantly in terms of OS (30 ± 7%, 59 ± 4%, 72 ± 5%), LFS (24 ± 7%, 46 ± 4%, 65 ± 5%) and relapse probability (CIR 72 ± 7%, 45 ± 4%, 25 ± 5%), all P<0.001. WT1 levels in bone marrow assayed using the standardized ELN method provide relevant prognostic information in de novo AML.
Sujet(s)
Antinéoplasiques/usage thérapeutique , Marqueurs biologiques tumoraux/génétique , Moelle osseuse/métabolisme , Récidive tumorale locale/génétique , Maladie résiduelle/génétique , Protéines WT1/génétique , Adolescent , Adulte , Sujet âgé , Marqueurs biologiques tumoraux/métabolisme , Moelle osseuse/effets des médicaments et des substances chimiques , Moelle osseuse/anatomopathologie , Chimiothérapie de consolidation , Femelle , Études de suivi , Dosage génique , Humains , Immunophénotypage , Leucémie aigüe myéloïde , Mâle , Adulte d'âge moyen , Récidive tumorale locale/diagnostic , Récidive tumorale locale/traitement médicamenteux , Récidive tumorale locale/mortalité , Stadification tumorale , Maladie résiduelle/diagnostic , Maladie résiduelle/traitement médicamenteux , Maladie résiduelle/mortalité , Réaction de polymérisation en chaîne , Pronostic , Induction de rémission , Études rétrospectives , Taux de survie , Protéines WT1/métabolisme , Jeune adulteRÉSUMÉ
Plasma-cholesterol concentrations were determined in 85 acute myelogenous leukemia patients. Measurements were repeated in 28 cases during remission. Mean plasma-cholesterol concentration (+/- SD) at diagnosis was 3.95 mmol/l (+/- 1.29). 47 patients (55.3%) had hypocholesterolemia (less than 3.87 mmol/l). Among the main clinical, hematologic and biochemical parameters, only high leukocyte counts were correlated with hypocholesterolemia. As far the FAB subtypes are concerned, the lowest cholesterol levels were observed in leukemias with monocytic component. However, although the same FAB subtypes showed significantly higher leucocytes counts than the other subtypes, both parameters were independently related to low cholesterol levels. Remission was associated with a significant increase in cholesterol levels in those patients with low cholesterol concentrations or high leukocyte counts at diagnosis. These results support the idea that initial hypocholesterolemia in acute myelogenous leukemia is related to the tumoral mass present at diagnosis.
